

## LANA Up-regulates VEGF Receptors through Daxx

antibody, and subjected to PCR to amplify a 98-bp fragment. The PCR product is designed to span the fourth ets motif (−54 to −51) that is thought to be indispensable for Flt-1 promoter activity (26). The anti-Daxx antibody precipitated the Flt-1 promoter as well as anti-Ets-1 antibody (Fig. 7C, lanes 6 and 7). The result indicated that Daxx as well as Ets-1 associated with Flt-1 promoter in ECs. Furthermore, HUVECs transfected with pIRES2-LANA-GFP or pIRES2-GFP as the control were sorted and subjected to ChIP assay with anti-Daxx antibody. The PCR product from the LANA-expressing cells (Fig. 7C, L, lane 9) was lower than that of control GFP-expressing cells (Fig. 7C, G, lane 8), indicating reduction of Daxx association with the promoter of the *Flt-1* gene in ECs.

### DISCUSSION

LANA is reported to have multiple functions in KS lesion. It interacts with many host cellular molecules: p53 (8), pRb (9), ATF4/CREB2 (29), CBP (30), c-Jun (31), RING3 (32), mSin3A (33), HP-1 (33), Dek (34), GSK-3b (10) and so on. In the present study, we identified Daxx as a new member of LANA-binding proteins. Daxx was prominently detected in our immunoaffinity system, but this system also detected previously reported LANA-interacting protein such as RING3 by Western blotting (data not shown). We showed the interaction between the two proteins *in vivo* (Fig. 1) and *in vitro* (Figs. 3 and 4), which indicates that Daxx and LANA directly bound to each other. Fluorescent immunostaining assay showed co-localization of LANA and Daxx in BCBL-1 cells, supporting LANA-Daxx interaction in cells (Fig. 2).

Daxx is reported to bind many cellular molecules, indicating its involvement in multiple cellular processes. Although Daxx could interact with proteins of cytoplasm or membrane, it also interacted with some transcription factors and localized sometimes in the nuclear matrix structure, PML NBs (promyelocytic leukemia nuclear bodies). PML NBs are thought to provide platforms for transcription regulation, DNA repair, apoptosis, DNA replication, RNA transport, and many viruses target PML NBs to pirate host functions (reviewed by Everett, Ref. 35). Ets-1 associates with a PML NBs protein, Sp100 (36). Therefore, it might be a strategy of KSHV that LANA targets Daxx of PML NBs to modulate the cellular function(s) of Ets-1.

Although most LANA-binding proteins are reported to interact through the C or N terminus of LANA, the critical domain for binding with Daxx seemed to be a central region, aa 321–344 of LANA (Fig. 3). The aa 320–431 of LANA consists mainly of aspartic acid and glutamic acid. It is reported that a transcriptional co-activator, CBP interacts through this acidic-rich region of LANA (30). This domain may have some roles in transcriptional regulation. On the other hand, although most Daxx-binding proteins interact around the C terminus of Daxx, a central domain containing the PAHs and the following region of Daxx appeared to be important for binding with LANA *in vivo* (Fig. 4). There was a discrepancy between *in vitro* and *in vivo* binding. Protein modification may be one possibility explaining *in vivo* binding activity. It is reported that Daxx is modified by hyperphosphorylation (13) and sumoylation (37). Because the sumoylation sites of Daxx are reported to be Lys<sup>630</sup> and Lys<sup>631</sup>, it is unlikely to affect the interaction. The hyperphosphorylation site on Daxx has not been identified, but it is possible to be

related to the binding. There may be other possibilities, for example, constructive interference by fused GST protein. PAH is a characteristic domain that is involved in transcriptional co-repressors such as mSin3 (38). It is interesting that mSin3A binds to aa 1–340 of LANA (28). There is a report that acetylated histone H4 interacts through PAH1 within Daxx, but no report that any other host molecule binds through this region of Daxx. As Daxx interacts with Ets-1 through the C-terminal region of Daxx (12), there may be no direct competition for Daxx between LANA and Ets-1.

Based on the interaction between LANA and Daxx (Figs. 1–4), we found that LANA induced VEGF receptors in ECs (Fig. 6) in accordance with the results of reporter assays (Fig. 5). Although expression level changes were not consistent for Flt-1 and KDR in protein (Fig. 6A) and mRNA (Fig. 6B), it may be caused by time point difference. This is the first report of the function of LANA in angiogenesis. It is reported that KSHV ORF74 (viral G-protein coupled receptor, v-GPCR) contributes to expression of VEGF receptors (39). Because ORF74 is expressed in the viral lytic infection cycle, it is unlikely that ORF74 is the only gene of KSHV that induces angiogenesis in KS. It is likely that some other factors such as VEGF and hypoxia-inducible factor (HIF) additionally affect on expression of these receptors in KS (40) (41).

As to the mechanism of activation of the receptor expression by LANA, we propose a hypothesis that LANA sequesters Daxx from Ets-1 (Fig. 7D), based on the results of co-immunoprecipitation (Fig. 7A) and ChIP assay (Fig. 7C). LANA slightly activated Ets-1 dependent Flt-1 expression without exogenous Daxx in the reporter assay (Fig. 5B). It is thought that LANA sequestered endogenous Daxx. However it is possible that LANA activates Flt-1 expression through an unidentified mechanism(s). At least LANA did not activate Flt-1 expression through up-regulation of Ets-1 expression (Fig. 6B). In human Flt-1 promoter, there are five Ets motifs and a CRE (cAMP response element). It is reported that co-existence of the fourth Ets motif, and the CRE is necessary for Flt-1 expression (26). LANA is reported to modulate the expression of a reporter plasmid with CRE, but the effect of LANA on CRE is repression (29). There is no CRE in the promoter of KDR.

Given that LANA induces VEGF receptors in KS lesion, we propose this hypothesis: Daxx binds Ets-1 to repress expression of VEGF receptors in normal ECs, while in KSHV-infected cells, LANA binds to Daxx to inhibit Daxx-Ets-1 interaction, resulting in the activation of Ets-1-dependent VEGF receptors. Furthermore, LANA-Daxx interaction might contribute to not only VEGF receptor gene expression but also to other Daxx-mediated gene regulation related to the pathogenesis of KS, PEL, and MCD malignancy.

*Acknowledgments*—We thank Dr. Kaoru Morishita (Daiichi Pharmaceutical Co., Ltd., Tokyo), and Dr. Runzhao Li (Medical University of South Carolina) for kindly providing plasmids. We thank Dr. Harutaka Katano (Department of Pathology, National Institute of Infectious Diseases) for providing BCBL-1 cells and useful advice, Dr. Kazuo Suzuki (Department of Bioactive Molecules, National Institute of Infectious Diseases) for useful discussion, and Eri Watanabe, Junko Kondo, and Yuki Hashimoto for their technical assistance.

**LANA Up-regulates VEGF Receptors through Daxx**
**REFERENCES**

1. Flore, O., Rafii, S., Ely, S., O'Leary, J. J., Hyjek, E. M., and Cesarman, E. (1998) *Nature* **394**, 588–592
2. Moore, P. S., and Chang, Y. (1998) *Am. J. Epidemiol.* **147**, 217–221
3. Dupin, N., Fisher, C., Kellam, P., Ariad, S., Tulliez, M., Franck, N., van Marck, E., Salmon, D., Gorin, I., Escande, J. P., Weiss, R. A., Alitalo, K., and Boshoff, C. (1999) *Proc. Natl. Acad. Sci. U. S. A.* **96**, 4546–4551
4. Russo, J. J., Bohenzky, R. A., Chien, M. C., Chen, J., Yan, M., Maddalena, D., Parry, J. P., Peruzzi, D., Edelman, I. S., Chang, Y., and Moore, P. S. (1996) *Proc. Natl. Acad. Sci. U. S. A.* **93**, 14862–14867
5. Katano, H., Sato, Y., Kurata, T., Mori, S., and Sata, T. (1999) *Am. J. Pathol.* **155**, 47–52
6. Ballestas, M. E., Chatis, P. A., and Kaye, K. M. (1999) *Science* **284**, 641–644
7. Garber, A. C., Shu, M. A., Hu, J., and Renne, R. (2001) *J. Virol.* **75**, 7882–7892
8. Friborg, J., Jr., Kong, W., Hottiger, M. O., and Nabel, G. J. (1999) *Nature* **402**, 889–894
9. Radkov, S. A., Kellam, P., and Boshoff, C. (2000) *Nat. Med.* **6**, 1121–1127
10. Fujimuro, M., Wu, F. Y., ApRhys, C., Kajumbula, H., Young, D. B., Hayward, G. S., and Hayward, S. D. (2003) *Nat. Med.* **9**, 300–306
11. Yang, X., Khosravi-Far, R., Chang, H. Y., and Baltimore, D. (1997) *Cell* **89**, 1067–1076
12. Li, R., Pei, H., Watson, D. K., and Papas, T. S. (2000) *Oncogene* **19**, 745–753
13. Hollenbach, A. D., Sublett, J. E., McPherson, C. J., and Grosveld, G. (1999) *EMBO J.* **18**, 3702–3711
14. Emelyanov, A. V., Kovac, C. R., Sepulveda, M. A., and Birshtein, B. K. (2002) *J. Biol. Chem.* **277**, 11156–11164
15. Kim, E. J., Park, J. S., and Um, S. J. (2003) *Nucleic Acids Res.* **31**, 5356–5367
16. Oikawa, T., and Yamada, T. (2003) *Gene (Amst.)* **303**, 11–34
17. Sacchi, N., de Klein, A., Showalter, S. D., Bigi, G., and Papas, T. S. (1988) *Leukemia* **2**, 12–18
18. Wernert, N., Raes, M. B., Lassalle, P., Dehouck, M. P., Gosselin, B., Vandebunder, B., and Stehelin, D. (1992) *Am. J. Pathol.* **140**, 119–127
19. Masood, R., Cai, J., Zheng, T., Smith, D. L., Naidu, Y., and Gill, P. S. (1997) *Proc. Natl. Acad. Sci. U. S. A.* **94**, 979–984
20. Masood, R., Cesarman, E., Smith, D. L., Gill, P. S., and Flore, O. (2002) *Am. J. Pathol.* **160**, 23–29
21. Sato, Y., Kanno, S., Oda, N., Abe, M., Ito, M., Shitara, K., and Shibuya, M. (2000) *Ann. New York Acad. Sci.* **902**, 201–205; discussion 205–207
22. Tang, D. G., and Conti, C. J. (2004) *Semin. Thromb. Hemost.* **30**, 109–117
23. Morishita, K., Johnson, D. E., and Williams, L. T. (1995) *J. Biol. Chem.* **270**, 27948–27953
24. Koizumi, S., Fisher, R. J., Fujiwara, S., Jorczyk, C., Bhat, N. K., Seth, A., and Papas, T. S. (1990) *Oncogene* **5**, 675–681
25. Yamagoe, S., Kanno, T., Kanno, Y., Sasaki, S., Siegel, R. M., Lenardo, M. J., Humphrey, G., Wang, Y., Nakatani, Y., Howard, B. H., Ozato, K., Xu, R. H., Peng, Y., Fan, J., Yan, D., Princler, G., Sredni, D., and Kung, H. F. (2003) *Mol. Cell Biol.* **23**, 1025–1033
26. Wakiya, K., Begue, A., Stehelin, D., and Shibuya, M. (1996) *J. Biol. Chem.* **271**, 30823–30828
27. Kappel, A., Schlaeger, T. M., Flamme, I., Orkin, S. H., Risau, W., and Breier, G. (2000) *Blood* **96**, 3078–3085
28. Krithivas, A., Young, D. B., Liao, G., Greene, D., and Hayward, S. D. (2000) *J. Gen. Virol.* **74**, 9637–9645
29. Lim, C., Sohn, H., Gwack, Y., and Choe, J. (2000) *J. Gen. Virol.* **81**, 2645–2652
30. Lim, C., Gwack, Y., Hwang, S., Kim, S., and Choe, J. (2001) *J. Biol. Chem.* **276**, 31016–31022
31. An, J., Sun, Y., and Rettig, M. B. (2004) *Blood* **103**, 222–228
32. Platt, G. M., Simpson, G. R., Mittnacht, S., and Schulz, T. F. (1999) *J. Virol.* **73**, 9789–9795
33. Lim, C., Lee, D., Seo, T., Choi, C., and Choe, J. (2003) *J. Biol. Chem.* **278**, 7397–7405
34. Krithivas, A., Fujimuro, M., Weidner, M., Young, D. B., and Hayward, S. D. (2002) *J. Virol.* **76**, 11596–11604
35. Everett, R. D. (2001) *Oncogene* **20**, 7266–7273
36. Wasyluk, C., Schlumberger, S. E., Criqui-Filipe, P., and Wasyluk, B. (2002) *Mol. Cell Biol.* **22**, 2687–2702
37. Jang, M. S., Ryu, S. W., and Kim, E. (2002) *Biochem. Biophys. Res. Commun.* **295**, 495–500
38. Spronk, C. A., Tessari, M., Kaan, A. M., Jansen, J. F., Vermeulen, M., Stunnenberg, H. G., and Vuister, G. W. (2000) *Nat. Struct. Biol.* **7**, 1100–1104
39. Bais, C., VanGeelen, A., Eroles, P., Mutlu, A., Chiozzini, C., Dias, S., Silverstein, R. L., Rafii, S., and Mesri, E. A. (2003) *Cancer Cell* **3**, 131–143
40. Chen, Z., Fisher, R. J., Riggs, C. W., Rhim, J. S., and Lautenberger, J. A. (1997) *Cancer Res.* **57**, 2013–2019
41. Elvert, G., Kappel, A., Heidenreich, R., Englmeier, U., Lanz, S., Acker, T., Rauter, M., Plate, K., Sieweke, M., Breier, G., and Flamme, I. (2003) *J. Biol. Chem.* **278**, 7520–7530



Original article

## GBV-B as a pleiotropic virus: distribution of GBV-B in extrahepatic tissues *in vivo*

Koji Ishii<sup>a</sup>, Sayuki Iijima<sup>b</sup>, Nobuyuki Kimura<sup>b</sup>, Young-Jung Lee<sup>b</sup>, Naohide Ageyama<sup>b</sup>, Shintaro Yagi<sup>d,1</sup>, Kenjiro Yamaguchi<sup>d</sup>, Noboru Maki<sup>d</sup>, Ken-ichi Mori<sup>d</sup>, Sayaka Yoshizaki<sup>a</sup>, Sanae Machida<sup>a,e</sup>, Tetsuro Suzuki<sup>a</sup>, Naoko Iwata<sup>c</sup>, Tetsutaro Sata<sup>c</sup>, Keiji Terao<sup>b</sup>, Tatsuo Miyamura<sup>a</sup>, Hirofumi Akari<sup>b,\*</sup>

<sup>a</sup> Department of Virology II, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162-8640, Japan

<sup>b</sup> Laboratory of Disease Control, Tsukuba Primate Research Center, National Institute of Biomedical Innovation, 1-1 Hachimandai, Tsukuba, Ibaraki 305-0843, Japan

<sup>c</sup> Department of Pathology, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162-8640, Japan

<sup>d</sup> Advanced Life Science Institute, Wako, Saitama 351-0112, Japan

<sup>e</sup> Department of Microbiology, Saitama Medical School, Moroyama-Cho, Iruma-Gun, Saitama 350-0495, Japan

Received 25 August 2006; accepted 16 January 2007

Available online 27 January 2007

### Abstract

GB virus B (GBV-B) infection of New World monkeys is considered to be a useful surrogate model for hepatitis C virus (HCV) infection. GBV-B replicates in the liver and induces acute resolving hepatitis but little is known whether the other organs could be permissive for the virus. We investigated the viral tropism of GBV-B in tamarins in the acute stage of viral infection and found that the viral genomic RNA could be detected in a variety of tissues. Notably, a GBV-B-infected tamarin with marked acute viremia scarcely showed a sign of hepatitis, due to preferential infection in lymphoid tissues such as lymph nodes and spleen. These results indicate that GBV-B as well as HCV is a pleiotropic virus *in vivo*. © 2007 Elsevier Masson SAS. All rights reserved.

**Keywords:** GB virus B; Hepatitis C virus; Tamarin; Surrogate model

### 1. Introduction

Over 100 million people worldwide are carriers of hepatitis C virus (HCV) and the viral infection is a significant cause of human morbidity and mortality; chronic HCV infection in many cases will lead to liver cirrhosis and hepatocellular carcinoma. Furthermore, HCV infection manifests a variety of extrahepatic, at least in part due to the extrahepatic tropisms of HCV, particularly lymphotropism diseases (for review see [1]).

Other than humans, only chimpanzees that are endangered as species can be productively infected by HCV. Together with ethical issues regarding animal experiments, it has become increasingly difficult to access chimpanzees for experimental studies. Tamarins (*Saguinus* species), one of the new world monkeys, develop acute, self-limited hepatitis upon infection with the GB virus B (GBV-B), which is most closely related to HCV [2–4]. Although the acute nature of GBV-B infection in tamarins has been distinguished this hepatitis from HCV infection in humans, recent studies demonstrated that tamarins could be persistently infected by GBV-B and developed chronic hepatitis [5,6]. Therefore, the GBV-B infection of tamarins is proposed as a good surrogate model for hepatitis C. While GBV-B appeared to infect liver, comprehensive documentation of the *in vivo* tropism of GBV-B has not been

\* Corresponding author. Tel.: +81 29 837 2121; fax: +81 29 837 0218.

E-mail address: akari@nibio.go.jp (H. Akari).

<sup>1</sup> Present address: Laboratory of Cellular Biochemistry, Department of Animal Resource Sciences, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo, Japan.

reported yet. A previous report that GBV-B RNA was observed in peripheral blood mononuclear cells (PBMCs) from a GBV-B-infected marmoset [7] suggests that GBV-B may be lymphotropic as well as HCV. Considering the close similarity between HCV and GBV-B, we examined the viral distribution and tropism in tamarins in the acute phase of the viral infection.

## 2. Materials and methods

### 2.1. Animals

Adult white-lipped and Red-handed tamarins (*Saguinus labiatus* and *Saguinus midas*, respectively) were housed in individual cages at the Tsukuba Primate Research Center. All animal studies were conducted in accordance with the protocols of experimental procedures that were approved by the Animal Welfare and Animal Care Committees of the National Institute of Biomedical Innovation and National Institute of Infectious Diseases. The details of tamarins used in this study were summarized in Table 1.

### 2.2. GBV-B infection in tamarins

GBV-B RNA was transcribed *in vitro* with T7 RNA polymerase (Promega, Madison, WI) from 10 µg of *Xho*I-digested pGBB [2] that harbors infectious cDNA for GBV-B (kind gift of Dr. J. Bukh, National Institutes of Health, USA). The integrity of the RNA was checked by electrophoresis through an agarose gel stained with ethidium bromide. Each transcription mixture (400 µg of GBV-B RNA) was diluted with 400 µl of ice-cold water and then immediately frozen on dry ice and stored at  $-80^{\circ}\text{C}$ . Transcription mixtures were injected into each tamarin intrahepatically. For transmission of GBV-B,

animals were infected intrahepatically with 100 µl of GBV-B infectious plasma containing  $8 \times 10^8$  genome equivalents (GE) of the viral RNA. Blood samples were periodically collected from the monkeys from femoral vein under anesthesia and were tested for plasma ALT level.

### 2.3. Quantification of GBV-B genomic RNA

GBV-B-infected tamarins were euthanized and perfused with saline thoroughly before the collection of specimens including plasma, PBMCs and a variety of tissues (esophagus, stomach, duodenum, jejunum, ileum, cecum, colon, rectum, liver, pancreas, submandibular gland, trachea, lung, bone marrow, thymus, spleen, submandibular lymph nodes, axillary lymph nodes, intestinal lymph nodes, mesenteric lymph nodes, inguinal lymph nodes, tonsil, heart, kidney, adrenal gland, bladder, brain, spinal cord, testis, uterus and ovary). GBV-B RNA from these specimens was quantified by a real-time, 5' exonuclease PCR (TaqMan) assay using a primer-probe combination that recognized a portion of the GBV-B capsid gene. The primers 558F [5'AACGAGCAAAGCGCAAAGTC] and 626R [5'CATCATGGATAACCAGCAATTTTGT] and probe 579P [5'6FAM-AGCGCGATGCTCGGCCTCGTATAMRA] [8] were obtained from PE Biosystems. The primers were used at 15 pmol/50 µl reaction, and the probe was used at 10 pmol/50 µl reaction. Synthesized GBV-B RNA was used as a reference standard of GBV-positive plasma. PBMCs were isolated from whole blood by density-gradient centrifugation. Approximately 10 mg of tissues were removed under sterile conditions and immediately homogenized in 1 ml of TRIzol (Invitrogen, Carlsbad, CA) to extract RNA. We set our lowest detection cutoff at  $10^2$  GE per ml. All the specimens were evaluated in duplicates and the averages were shown.

Table 1  
Summary of the results of GBV-B RNA levels in the tissues of the virus-infected tamarins

		Tm3	Tm4	Tm5	Tm6
Animals		<i>S. labiatus</i>	<i>S. midas</i>	<i>S. labiatus</i>	<i>S. midas</i>
Sex		Female	Female	Male	Female
GBV-B inoculum		Plasma	Plasma	RNA	RNA
Weeks at necropsy		4	4	3	ND <sup>a</sup>
ALT		321	522	38	554
Viral loads in:					
Blood	Plasma	$3.8 \times 10^8$	$5.9 \times 10^8$	$1.3 \times 10^{10}$	$2.8 \times 10^9$
	PBMC	270	1630	35650	ND
Spleen		(-) <sup>b</sup>	540	5980	ND
Lymph nodes	Inguinal	(-)	(-)	3090	ND
	Intestinal	(-)	(-)	640	ND
Liver		70080	33480	16080	ND
Kidney		(-)	(-)	380	ND
Testis				600	ND
Ovary		1290	150		ND
Bone marrow		120	(-)	750	ND

Viral loads in each tissues were presented as GE/mg except for plasma (GE/ml) and PBMC (GE/ $10^6$  cells). Data for Tm6 were obtained at week 4.

<sup>a</sup> ND: not done.

<sup>b</sup> (-): undetectable.

#### 2.4. Detection of anti-GBV-B core and NS3 antibodies by ELISA

The TrpE-core (aa 1 to 132) fusion protein and TrpE-NS3 (aa 1135 to 1378) fusion protein, representing a portion of NS3 identified as being immunogenic in infected animals [9], was expressed in *Escherichia coli* [10] to serve as an antigen to generate polyclonal rabbit antisera. Tamarin sera were tested for the presence of antibodies to GBV-B core and NS3 by ELISA as described previously [8].

#### 2.5. Cloning of entire GBV-B genome from plasma, liver and PBMCs of infected tamarins

GBV-B RNA was isolated from plasma, liver and PBMCs as described above. GBV-B cDNA was synthesized using SuperScript reverse transcriptase II (Invitrogen) with GB-5145R primer (5'-GCG AGT GCG GCT GTC CCA GAA GTA TTG ACT-3') or GB-9051R primer (5'-AAT TTG GGG GTT CAG CTG ATG GCT AAT CCA-3'). After RNase H (Invitrogen) treatment at 42 °C, a cDNA mixture was subjected to PCR with LA-taq DNA polymerase (TaKaRa), GB-5145R primer and GB-35S primer (5'-ACC ACA AAC ACT CCA GTT TGT TAC ACT CCG CTA GG-3') or GB-9051R primer and GB-3999S primer (5'-CGT ACG GCG TGA ATC CAA ATT GCT ATT TTA-3') for 30 cycles of denaturation at 94 °C for 20 s and extension at 68 °C for 5 min. PCR products were purified from the gel using a QIA-quick gel kit (Qiagen), and then cloned into pGEM-T Easy vector (Promega). Four clones of each fragment were determined using a CEQ-2000XL analysis system with a DTCS quick start kit and GBV-B specific primers according to the manufacturer's instructions. Sequence data were analyzed on Macintosh computers with the Sequencer (Gene Code Corp.) and MacVector (Accelrys) software packages.

#### 2.6. Synthesis of positive and negative standard RNAs for RT-PCR controls

Recombinant positive and negative strand RNAs were generated from pGBB containing 3' sequences of GBV-B. Positions 8569–9359 were amplified and inserted into pGEM-T easy vector. Clones were selected for sense and antisense orientation of the insert corresponding to positive and negative strands, respectively. Ten micrograms of the selected plasmids were linearized using *Pst*I and positive- and negative-strand RNAs were synthesized by transcription from the upstream T7 RNA polymerase promoter by Ambion MEGAscript T7 kit (Ambion, Austin, TX).

#### 2.7. Detection of strand-specific viral RNA by tagging PCR system

One microgram of total RNA obtained from tissues or cells was subjected to RT-PCR. cDNAs were synthesized using Superscript III first strand synthesis system (Invitrogen). In order to overcome the detection of falsely primed cDNA products and make the PCR system strand-specific, additional

nucleotides (TCATGGTGGCGAATAA) were added to the 5' end of the reverse transcription primer (5'-TCATGGTGGCGAATAATTGGATTAGCCATCAGCTGAACC-3'), forming a "tag" (underlined) [11,12]. This "tag" sequence was neither complementary nor homologous to any part of the GBV-B genome. PCR amplification of a tagged cDNA was performed using only the tag portion of the cDNA primer (5'-TCATGGTGGCGAATAA-3') as one of the primers and a GBV-B specific oligonucleotide for the opposing primer (5'-CTTGGTACTACGCTCTGCACA-3', positions 9339–9359). For the first round of PCR using 2 µl of cDNA in a final volume of 25 µl, the reactions were performed using a TaKaRa PCR kit (TaKaRa) with following conditions; a 20 s and 94 °C denaturation step followed by 20 s and 55 °C annealing and 2 min and 72 °C extension steps. After 30 cycles of first round amplification, 2 µl of reaction samples were subjected to 30 cycles of nested PCR using 5'-TTTTAGGGCAGCGCAACAG-3' (positions 9105–9124) and 5'-CACACAGCCAGGACTCCTCA-3' (positions 9260–9279) as primers.

#### 2.8. Histopathology

Five tamarin livers were used in this study. Of these, three livers were from GBV-B-infected tamarins (Table 1), and two were from uninfected tamarins. Liver samples obtained by necropsy were fixed with 4% paraformaldehyde, embedded in paraffin, and cut into 4 µm thick-sections. Deparaffinized sections were stained with hematoxylin and eosin (H&E) for histopathological analyses. To investigate apoptotic cells in the livers, we also examined both DNA fragmentation and immunohistochemistry for an active form of caspase-3. To diminish autofluorescence mainly caused by lipofuscin, sections were pre-stained with 1% Sudan black B. DNA fragmentation was evaluated by a TUNEL assay with an ApopTag Direct *In Situ* Apoptosis Detection Kit (Chemicon International, Temecula, CA) according to the manufacturer's instructions. Briefly, the specimens were digested with a solution of proteinase K (20 µg/ml) in PBS for 5 min and then incubated with terminal deoxynucleotidyl transferase (TdT) and fluorescein-labeled nucleotides (ApopTag Direct) in a humid atmosphere at 37 °C for 1 h. Specimens were viewed with a BX-FLA fluorescence microscope (Olympus, Tokyo, Japan). To control for nonspecific incorporation of nucleotides and nonspecific binding of TdT, cells were treated with proteinase K as usual, but staining was performed in the absence of active TdT. This served as a negative control. In parallel, immunohistochemistry for an active form of caspase-3 was examined by using an FITC-conjugated monoclonal antibody against the active caspase-3 (C92-605; BD Pharmingen, San Jose, CA) in order to confirm the degree of apoptotic cells detected by TUNEL staining. Sections were deparaffinized followed by autoclaving for 5 min at 121 °C, and then incubated free floating in the primary antibody solution overnight at 4 °C. Following brief washes, sections were then incubated with DAPI (1:800; Santa Cruz Biotechnology, Santa Cruz, CA) for 1 h at room temperature. These sections were examined with a Digital Eclipse C1 confocal microscope (Nikon, Japan).

### 3. Results

#### 3.1. GBV-B infection in tamarins

Firstly, two tamarins were intrahepatically inoculated with RNA transcripts from GBV-B infectious molecular clone pGBB (Fig. 1). Both monkeys showed viremia at 2 weeks post inoculation; peak viral titers in plasma reached up to  $10^9$  GE/ml and both monkeys developed hepatitis with dramatically elevated plasma ALT levels. The viremia was maintained up to 8 weeks, followed by rapid decline in parallel with the resolution of the ALT abnormalities. Within 6–8 weeks of the inoculation, the development of antibodies reactive with the viral core and NS3 proteins was observed (Fig. 1). Multiple plasma samples collected at later time points contained no detectable viral RNA and showed no ALT abnormalities; however, antibodies against GBV-B core and NS3 proteins were maintained at relatively high levels at least until 28 weeks after inoculation (Fig. 1). These results confirmed that inoculation of GBV-B viral RNA caused acute hepatitis in parallel with typical viremia in tamarins.

Next, in order to examine the tissue tropism of GBV-B *in vivo*, four tamarins were inoculated intrahepatically with week 2 plasma of tamarin Tm1 containing  $8 \times 10^8$  GE of GBV-B (Tm3 and Tm4) or synthetic GBV-B RNA as described above (Tm5 and Tm6). These tamarins developed a typical acute infection that were marked by high levels of viremia, indicating that inoculation of either viral RNA or plasma of the infected tamarin resulted in comparable outcome (Fig. 2). It is noteworthy that in Tm5 the plasma ALT level was scarcely elevated in contrast with other three tamarins during the acute period of GBV-B infection, although this tamarin developed highest viremia ( $1.3 \times 10^{10}$  GE/ml).

#### 3.2. Histopathological analyses of GBV-B infection

Histopathological analyses in Tm3 and Tm4 livers showed inflammatory responses including inflammatory cell invasions around central and/or portal veins and hemorrhages, hepatocytic degenerations, and disruptions of sinusoids (Fig. 3A,B,E,F). Although there were only minimal pathological changes, hepatocytic degenerations and dilation of sinusoids were also found in the Tm5 liver (Fig. 3C and G) in contrast to uninfected tamarins (Fig. 3D and H, data not shown). To further evaluate the levels of apoptotic hepatocytes in these monkeys, we employed two different methods, detecting fragmented DNA (TUNEL assay) and an active form of caspase-3 as previously described [13]. It was found that substantial numbers of fragmented DNA-positive cells were observed in the Tm3 and Tm4 livers while much less in the Tm5 liver (Fig. 3I–K). Consistent results were obtained when the active form of caspase-3 was stained (Fig. 3M–O). On the other hand, we found neither DNA fragmentation nor caspase-3 activation in uninfected tamarin livers (Fig. 3L and P, data not shown). The minimal levels of pathological changes in the Tm5 liver were well correlated with a lower level of plasma ALT in Tm5 (Fig. 2, Table 1).

#### 3.3. Tissue distribution of GBV-B

The results described above suggested the possibility that the substantial levels of viral replication occurred in other tissues rather than in the liver of Tm5. To ascertain the possibility, we euthanized three tamarins (Tm3, Tm4 and Tm5) and the viral levels in a variety of tissues were compared. Table 1 summarizes the data obtained in this experiment. It is reasonable to consider that GBV-B replicated in the liver accounts for majority of the viral load *in vivo*. However,




Fig. 1. Course of GBV-B infection in tamarins Tm1 and Tm2. Synthesized infectious RNA transcript of GBV-B from a pGBB molecular clone was inoculated into each tamarin intrahepatically. Plasma samples were collected from each tamarin at 2-week intervals post inoculation. The viral RNA copies, ALT levels, and titers of anti-viral antibodies (anti-core and anti-NS3) in the plasma samples until 28 weeks after inoculation were shown.

substantial levels of GBV-B RNA were detected not only in the liver but also in a variety of extrahepatic tissues such as hemolymphoid and genital tissues, suggesting that GBV-B may infect and replicate in these organs. Notably, the viral RNA levels of Tm5 were much greater in the lymphoid tissues but lower in the liver as compared with those of other two tamarins, indicating that the highest plasma viral load in Tm5 derived from extrahepatic tissues, mainly hemolymphoid tissues. We could not detect GBV-B RNA from other tissues tested (data not shown). From these results, we concluded that the preferential distribution of GBV-B in the extrahepatic tissues rather than in the liver of Tm5 may attribute to the highest plasma viral load in spite of the mild disorder and the lower viral load in the liver.

In addition, the unique viral distribution implied that the GBV-B disseminated in Tm5 might acquire novel tissue tropism as a result of genomic mutation. To ascertain the possibility, we amplified the entire viral genomes by RT-PCR from the liver, PBMCs and plasma collected from Tm5 at euthanasia and compared with the original nucleotide sequence. The sequences determined were completely identical to the original sequence of GBV-B (data not shown), indicating that the sequence heterogeneity of GBV-B was not responsible for the different tropism observed in Tm5 and thus GBV-B intrinsically exhibits pleiotropism in a host-dependent manner.

### 3.4. Detection of strand-specific viral RNA in the tamarin tissues

To confirm that the virus was actually replicated in the tissues other than the liver, we sought to differentially determine negative-strand viral RNA which is shown to be a viral replication intermediate in case of HCV. We thus newly developed an assay system for detecting replication intermediate of GBV-B.

To determine the sensitivity of this method, synthetic positive- and negative-strand GBV-B transcripts (ranging from  $10^8$  to  $10^0$  copies of GBV-B) in 100-fold serial dilutions were subjected to RT-PCR. As shown in Fig. 4A, at least 100 copies of GBV-B negative-strand RNA could be detected by this method. When the primer for cDNA synthesis was omitted, no PCR products were obtained (Fig. 4A, negative control), indicating that the PCR signals were derived specifically from the GBV-B negative-strand RNA. In the presence of  $10^8$  copies of positive-strand HCV RNA, false positive PCR signals appeared (Fig. 4A). We then analyzed the samples from liver, spleen, pancreas, stomach and PBMCs from Tm5 using the GBV-B strand-specific PCR assay and found that the negative-strand viral RNAs were detected in the liver, spleen and PBMC samples (Fig. 4B). No negative-strand or replicating forms of the virus were detected from RNA extracted from pancreas, stomach and HeLa cells.




Fig. 2. Acute course of GBV-B infection in tamarins (Tm3 and Tm4) by *in vivo* passage of plasma ( $7.9 \times 10^8$  GE/head) obtained from the GBV-B RNA-inoculated Tm1 in comparison with GBV-B RNA transcript-inoculated tamarins (Tm5 and Tm6). The viral RNA copies and ALT levels in the plasma samples collected from each tamarin were indicated.




Fig. 3. Photomicrographs of liver sections from Tm3 (A, E, I, M), Tm4 (B, F, J, N), Tm5 (C, G, K, O), and an uninfected tamarin (D, H, L, P). A–H show sections with H&E staining, while I–L and M–P indicate sections with a TUNEL assay and immunohistochemistry for an active form of caspase-3, respectively. Sections immunostained for an active form of caspase-3 (green fluorescent) were counterstained with DAPI (blue fluorescent). Scale bars: 100  $\mu$ m.

#### 4. Discussion

GBV-B is most closely related to HCV and induces acute resolving hepatitis in tamarins. It is therefore reasonable that GBV-B has been considered to be a hepatotropic virus; in this study, however, we show for the first time that GBV-B is a pleiotropic virus and can disseminate to not only liver but also a variety of extrahepatic tissues such as hemolymphoid and genital tissues. Of note, there is ample evidence that persistent HCV infection manifests a variety of extrahepatic diseases, at least in part due to the extrahepatic tropisms of HCV (for review see [1]). This also suggests that extrahepatic tissues may serve as alternative reservoirs for HCV, while further analyses should still be required to understand the viral dynamics *in vivo*. Considering the similar pleiotropism of HCV and GBV-B, our results support and extend the usefulness of New World primates infected with GBV-B as a surrogate model for the study of pathogenesis and tropism of HCV infection.

Tamarins infected with GBV-B generally develop semi-acute viremia, of which peak levels regularly ranged from  $10^7$  to  $10^9$  GE/ml on the basis of previous reports [2,5,6,

14,15]. From this point of view, the peak viremia ( $1.3 \times 10^{10}$  GE/ml) in Tm5 euthanized at the acute phase of the viral infection appeared to be much greater than other cases. It seems likely that in Tm5 the lymphoid tissues but not liver were responsible for the highly efficient viral production, because (i)




Fig. 4. (A) Titration of synthetic GBV-B RNA transcripts. Synthetic RNA transcripts corresponding to the positive- and negative-strands of part of the GBV-B were serially diluted and each transcript was subjected to amplification using strand-specific RT-PCR to determine the specificity and sensitivity of the assays. (B) Detection of negative-strand GBV-B RNA from various tissues. One microgram of total RNA obtained from tissues or cells was subjected to RT-PCR.



viral titer in the liver was lowest among three monkeys, which was consistent with minimal plasma ALT level and liver damage; (ii) yet, Tm5 exhibited highest viremia levels, (iii) the viral RNA levels in PBMCs, spleen and inguinal and intestinal lymph nodes of Tm5 were much greater than others, and (iv) we could detect negative-strand GBV-B RNA from not only liver but also spleen and PBMCs. Supposing that the entire virus in Tm3 plasma ( $3.8 \times 10^8$  GE/ml) was produced in the liver of which RNA titer was highest among tamarins, most of the virus in Tm5 plasma ( $1.3 \times 10^{10}$  GE/ml) should be derived from extrahepatic tissues. Taken together, our data demonstrate preferential dissemination of GBV-B in extrahepatic tissues. In order to further define the cell type(s) in which GBV-B replicates efficiently, *in situ* histological analysis should be needed as indicated in the case of HCV [16].

It was possible that differential lymphotropism among GBV-B-infected tamarins could be due to adaptive mutation in the viral genome. From this point of view, we cloned the viral RNA obtained from plasma and liver; however, we did not find any sequence heterogeneity in the viral genome (data not shown). Furthermore, challenge of Tm5 plasma to naïve tamarins developed typical semi-acute hepatitis with regular viremia and did not reproduce the preferential lymphotropism (data not shown). These results indicate that GBV-B intrinsically has pleiotropism in a host-dependent manner. It is possible that multiple surface molecules in the host cells, which act as alternative receptors, would determine the pleiotropism of GBV-B. It remains to be investigated whether host molecules which are used as receptors for HCV [17] would also be used by GBV-B.

Histopathological studies showed the inflammatory responses in Tm3 and Tm4 livers; especially, the Tm4 liver developed strong degenerative changes, which was consistent with high ALT levels (Fig. 2G,H). Furthermore, the livers of Tm3 and Tm4 showed substantial proportions of apoptotic cells as revealed by greater signals of DNA fragmentation and caspase-3 activation, both of which were popular markers of apoptosis, than those in Tm5 (Fig. 3). It needs to be clarified whether such cytopathic effects could be directly induced by GBV-B infection into hepatocytes or whether effector cytotoxic T lymphocytes would be responsible for the cytopathicity.

#### Acknowledgments

We are grateful to Dr. Jens Bukh for providing pGBB. We also thank Mami Matsuda, Makiko Yahata and Tetsu Shimoji for technical assistance and members of Corporation for Production and Research of Laboratory Primates for the handling and care of the monkeys. This work was supported by a Health and Labour Science Research Grant from the Ministry of Health, Labour, and Welfare, Japan, and from New

Energy and Industrial Technology Development Organization (NEDO) of Japan.

#### References

- [1] V. Agnello, F.G. De Rosa, Extrahepatic disease manifestations of HCV infection, *J. Hepatol.* 40 (2004) 341–352.
- [2] J. Bukh, C.L. Apgar, M. Yanagi, Toward a surrogate model for hepatitis C virus: An infectious molecular clone of the GB virus-B hepatitis agent, *Virology* 262 (1999) 470–478.
- [3] A.S. Muerhoff, et al., Genomic organization of GB viruses A and B: two members of the Flaviviridae associated with GB agent hepatitis, *J. Virol.* 69 (1996) 5621–5630.
- [4] J.N. Simons, et al., Identification of two flavivirus-like genomes in the GB hepatitis agent, *Proc. Natl. Acad. Sci. USA.* 92 (1995) 3401–3405.
- [5] A. Martin, F. Bodola, D.V. Sangar, K. Goettge, V. Popov, R. Rijnbrand, R.E. Lanford, S.M. Lemon, Chronic hepatitis associated with GB virus B persistence in a tamarin after intrahepatic inoculation of synthetic viral RNA, *Proc. Natl. Acad. Sci. USA.* 100 (2003) 9962–99627.
- [6] J.H. Nam, K. Faulk, R.E. Engle, S. Govindarajan, M. St Claire, J. Bukh, In vivo analysis of the 3' untranslated region of GB virus B after in vitro mutagenesis of an infectious cDNA clone: persistent infection in a trans-fected tamarin, *J. Virol.* 78 (2004) 9389–9399.
- [7] J.R. Jacob, K.C. Lin, B.C. Tennant, K.G. Mansfield, GB virus B infection of the common marmoset (*Callithrix jacchus*) and associated liver pathology, *J. Gen. Virol.* 85 (2004) 2525–2533.
- [8] B. Beames, D. Chavez, B. Guerra, L. Notvall, K.M. Brasky, R.E. Lanford, Development of a primary tamarin hepatocyte culture system for GB virus-B: a surrogate model for hepatitis C virus, *J. Virol.* 74 (2000) 11764–11772.
- [9] T.J. Pilot-Matias, A.S. Muerhoff, J.N. Simons, T.P. Leary, S.L. Buijk, M.L. Chalmers, J.C. Erker, G.J. Dawson, S.M. Desai, I.K. Mushahwar, Identification of antigenic regions in the GB hepatitis viruses GBV-A, GBV-B, and GBV-C, *J. Med. Virol.* 48 (1996) 329–338.
- [10] K. Tsukiyama-Kohara, N. Iizuka, M. Kohara, A. Nomoto, Internal ribosome entry site within hepatitis C virus RNA, *J. Virol.* 66 (1992) 1476–1483.
- [11] R.L. Chaves, J. Graff, A. Normann, B. Flehmig, Specific detection of minus strand hepatitis A virus RNA by Tail-PCR following reverse transcription, *Nucleic Acids Res.* 22 (1994) 1919–1920.
- [12] J. Mellor, G. Haydon, C. Blair, W. Livingstone, P. and Simmonds, Low level or absent in vivo replication of hepatitis C virus and hepatitis G virus/GB virus C in peripheral blood mononuclear cells, *J. Gen. Virol.* 79 (1998) 705–714.
- [13] H. Akari, S. Bour, S. Kao, A. Adachi, K. Strelbel, The human immunodeficiency virus type 1 accessory protein Vpu induces apoptosis by suppressing the nuclear factor kappaB-dependent expression of antiapoptotic factors, *J. Exp. Med.* 194 (2001) 1299–1311.
- [14] A. Sbardellati, E. Scarselli, E. Verschoor, A. De Tomassi, D. Lazzaro, C. Traboni, Generation of infectious and transmissible virions from a GB virus B full-length consensus clone in tamarins, *J. Gen. Virol.* 82 (2001) 2437–2448.
- [15] R.E. Lanford, D. Chavez, L. Notvall, K.M. Brasky, Comparison of tamarins and marmosets as hosts for GBV-B infections and the effect of immunosuppression on duration of viremia, *Virology* 311 (2003) 72–80.
- [16] E.J. Gowans, Distribution of markers of hepatitis C virus infection throughout the body, *Semin. Liver Dis.* 20 (2000) 85–102.
- [17] L. Cocquerel, C. Voisset, J. Dubuisson, Hepatitis C virus entry: potential receptors and their biological functions, *J. Gen. Virol.* 87 (2006) 1075–1084.



## Efficient regulation of viral replication by siRNA in a non-human primate surrogate model for hepatitis C

Takanori Yokota <sup>a,\*</sup>, Sayuki Iijima <sup>b</sup>, Takayuki Kubodera <sup>a,c</sup>, Koji Ishii <sup>d</sup>,  
Yuko Katakai <sup>e</sup>, Naohide Ageyama <sup>b</sup>, Yingwei Chen <sup>a</sup>, Young-Jung Lee <sup>b</sup>,  
Toshinori Unno <sup>a</sup>, Kazutaka Nishina <sup>a</sup>, Yuki Iwasaki <sup>b</sup>, Noboru Maki <sup>f</sup>,  
Hidehiro Mizusawa <sup>a,c</sup>, Hirofumi Akari <sup>b,\*</sup>

<sup>a</sup> Department of Neurology and Neurological Science, Graduate School, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan

<sup>b</sup> Laboratory of Disease Control, Tsukuba Primate Research Center, National Institute of Biomedical Innovation, 1 Hachimandai, Tsukuba 305-0843, Japan  
<sup>c</sup> 21 century COE Program on Brain Integration and its Disorders, Japan

<sup>d</sup> Department of Virology II, National Institute of Infectious Diseases, Toyama 1-23-1, Shinjuku-ku, Tokyo 162-8640, Japan

<sup>e</sup> Corporation for Production and Research of Laboratory Primates, 1 Hachimandai, Tsukuba 305-0843, Japan

<sup>f</sup> Advanced Life Science Institute, Inc, 2-10-23 Maruyamadai, Wako 351-0112, Japan

Received 20 June 2007

Available online 16 July 2007

### Abstract

RNA interference (RNAi) represents a new technology which could offer potential applications for the therapeutics of human diseases. RNAi-mediated therapy has recently been shown to be effective toward infectious diseases in *in vitro* and rodent models, however, it remains unclear whether RNAi therapy with systemic application could be effective in primates. In this study, we examined if RNAi therapy could be effective toward infectious diseases by using a non-human primate surrogate model for hepatitis C. Administration into marmosets of cationic liposome-encapsulated siRNA (CL-siRNA) for GB virus B (GBV-B), which is most closely related to hepatitis C virus, repressed GBV-B replication in a dose-dependent manner. Especially, 5 mg/kg of the CL-siRNA completely inhibited the viral replication. Since the serum interferons (IFNs) were induced by CL-siRNA *in vivo*, inhibition of viral regulation by anti-GBV-B CL-siRNA may include an antiviral effect of IFN. However, contribution of induced IFN may be partial, since the control CL-siRNA which induced a stronger IFN response than GBV-B CL-siRNA could only delay the viral replication. Our results suggest the feasibility of systemic administration of CL-siRNA as an antiviral strategy.

© 2007 Published by Elsevier Inc.

**Keywords:** siRNA; Hepatitis C; Marmoset; Interferon; GB virus B

RNA interference is a powerful tool for silencing gene expression and has spurred considerable interest in its experimental and therapeutic potential. RNAi has been characterized as a cellular process of post-transcriptional gene silencing. An RNaseIII-like enzyme, called Dicer, cleaves double stranded RNA (dsRNA) in to 21–23 nucle-

otide RNA duplex, termed small interfering RNAs (siRNAs). siRNAs are unwound in the RNA-induced-silencing-complex (RISC), and single-stranded siRNAs then act as a guide to substrate selection, leading to the cleavage of a homologous target RNA molecule [1].

Hepatitis C virus (HCV) infection contributes significantly to human morbidity and mortality worldwide. It is estimated that 40–60% of infected individuals progress to chronic liver disease, and many of these patients develop liver cirrhosis and hepatocellular carcinoma [2]. Currently,

\* Corresponding authors.

E-mail addresses: tak-yokota.nuro@tmd.ac.jp (T. Yokota), akari@ni-bio.go.jp (H. Akari).

the only treatment available for patients with chronic HCV infections is combinational therapy with interferon (IFN) and ribavirin. The standard therapy is only effective for approximately 50% of patients with chronic HCV hepatitis [3]. Therefore, there is a great need for less complicated and more generally efficient therapeutics for HCV infection.

We and others reported that the synthetic siRNA and the siRNA-expressing adenovirus targeting 5'-UTR of HCV genome efficiently and specifically inhibited the HCV replication *in vitro* [4–6]. Other than humans, only chimpanzees can be productively infected by HCV. Together with ethical issues it has become increasingly difficult to access chimpanzees for experimental studies. The new world monkeys, tamarins and marmosets, undergo hepatitis upon infection with the GBV-B, which is most closely related to HCV. The significant similarity between HCV and GBV-B at the genomic and biochemical levels led to the proposal of the GBV-B/monkey system as a good surrogate model for hepatitis C [7,8]. Taking advantage of this non-human primate surrogate model, we investigated the feasibility of siRNA-mediated therapy against infectious diseases caused by pathogenic viruses.

**Materials and methods**

*Preparation of siRNA.* The sequence of siRNA for GBV-B was cucguagaccguagcacau dTdT in the sense strand and augu-gcuacggucuaacgagdTdT in the antisense strand which was designed to target the GBV-B RNA (Fig. 1). The sequence of control siRNA for




Fig. 1. Predicted secondary structure of the 5'-untranslated region around the target site (italic) in the HCV and GBV-B genome (nucleotide 114–137 and 285–359 of HCV, and 263–255 and 390–467 of GBV-B), and the sense sequences of siRNA.




Fig. 2. Effects of the siRNA oligonucleotides on expression of GBV-B-reporter gene in culture cells. (A) and liver of mice (B).

experiments of Fig. 2A and B was uua ugc cga ugc cgu cac a dTdT in the sense strand and ugu gac gcg auc ggc aua a dTdT in the antisense strand which was designed to target beta-galactosidase RNA, and that for experiments of Figs. 3 and 4 was gct atg aaa cga tat ggg c dTdT in the sense strand and g ccc aua ugc uuu cau ugc dTdT in the antisense strand which was designed to target firefly-luciferase RNA. siRNA oligonucleotides were chemically synthesized and purified by reverse-phase high-performance liquid chromatography, while the unconjugated RNA oligonucleotides were purified by anion-exchange high-performance liquid chromatography. The sense and antisense strands were annealed at 95 °C for 1 min followed by slow cooling in RNase free water. Positively charged liposomes containing cationic lipid analogue were synthesized at Nippon Shinyaku Co., as described previously [9]. To prepare CL-siRNA,

annealed siRNA was added to the same volume of liposome solution with sonication. The ratio of oligonucleotide to LIC-101 was 1:16 (w/w).

**Cells culture and transfection.** The human embryonic kidney cell line, 293 T, was maintained in Dulbecco's modified minimal essential medium (Sigma, St. Louis, Missouri) supplemented with 10% fetal calf serum at 37 °C under 5% CO<sub>2</sub>. Transfections of the siRNA oligonucleotides and the plasmids were performed in 24-well plates using Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA) as per the manufacturer's instructions. GBV-B-RNA-reporter gene vector, pGBV-B-Rluc, was used as a target, which expressed mRNA consisting of GBV-B 5'-untranslated region and upstream part of the core region (nucleotide 1–377) connected with upstream of *renilla* luciferase (RLuc) gene. Fifty nanograms of the pGBV-B-Rluc and 2 and 25 nM of siRNA were transiently transfected with 20 ng of firefly luciferase (FLuc)-expressing plasmid (pRL-RSV, Promega). The RLuc activity was adjusted by the FLuc activity, to normalize the transfection efficiency.

**Luciferase assays.** Luciferase activities were quantified with a luminometer (Lumat LB9501, Promega) using the Bright-Glo Luciferase Assay System (Promega). Assays were performed in triplicate and the results expressed as means ± SD as percentages of controls.

**Animals.** Male BALB/c or ICR mice, 9 weeks of age, were obtained from CLEA Japan and subject to a 2-week quarantine and acclimation period before use. Male juvenile common marmosets (*Callithrix jacchus*) were housed in individual cages at the Tsukuba Primate Medical Center. All animal studies were conducted in accordance with the protocols of experimental procedures which were approved by the Animal Welfare and Animal Care Committee of the National Institute of Biomedical Innovation and Tokyo Medical and Dental University.

**In vivo efficacy experiments in mice.** For the *in vivo* delivery of the siRNA to the liver of mice and monkeys, we used a novel cationic liposome that was synthesized by Nippon Shinyaku Co., Ltd. This cationic liposome was reported to be a good vehicle for the delivery of nucleic acid polymers and siRNAs to the liver when it was administered intravenously [9,10] or to the bladder by intravesical administration [11]. For the delivery of plasmid DNA to the liver of mice we used the hydrodynamic injection method in which a large volume of nucleotides solution was rapidly injected from tail vein [12]. *Three mice for each group were examined.* 5.0 mg/kg GBV-B or control CL-siRNA was administered as a regular intravenous injection from the tail vein in 0.2 ml 10% maltose over a period of 1–3 s. Three minutes later, the 50 µg of the pGBV-B-Rluc and 20 µg of pRL-RSV plasmids in a volume equivalent to 5% of the body weight were rapidly injected in 3–5

into the mouse tail vein according to the hydrodynamic injection method. Phosphate buffer saline (PBS) was used as a carrier solution for injection. Successful injection was monitored when the conjunctiva of mouse became transiently anemic and confirmed by the luciferase activity in the liver.

**In vivo efficacy experiments in monkeys.** Negative control (n = 2; with or without control siRNA) and treatment group (n = 3; 1.0, 2.5 and 5.0 mg/kg of anti-GBV-B siRNA) were employed in this study. GBV-B-infectious serum obtained from a tamarin [8] was intrahepatically inoculated with the GBV-B RNA. The siRNA to GBV-B and control siRNA formulated by the cationic liposome, or just 10% maltose (sham) was administered by standard intravenous injection via the saphenous vein of the marmosets for three days. On the second day, the GBV-B infectious serum (1.3 × 10<sup>9</sup> viral RNA copies/inoculum) was directly injected to the liver of five marmosets. Blood samples were periodically collected from the femoral vein of the monkeys under anesthetization. GBV-B RNA in plasma from the monkeys was quantified by a real-time, 5' exonuclease PCR (TaqMan) assay using a primer-probe combination that recognized a portion of the GBV-B capsid gene as previously described [8]. The Platelet cell counts were performed at FALCO Biosystems, Co., Ltd.

**Measurement of IFNs in mice and monkeys.** The siRNA/cationic liposome was injected from tail vein of ICR mice or saphenous vein of the marmosets. Blood samples were taken 3 h after the injection. Mouse IFN-α levels were quantified by using sandwich ELISA kits for mouse IFNs (PBL Biomedical Laboratories, Biosource). Marmoset IFN-α and -γ levels were by using sandwich ELISA kits for human and rhesus macaque IFN, respectively (U-CyTech bioscience) according to the manufacturer's instructions. Assays were performed in duplicate and the results expressed as means ± SD as percentages of controls.

## Results

We selected the siRNA-targeting site to the GBV-B genome from its 5'-UTR, the most conservative portion in both GBV-B and HCV genomes [13], to protect the siRNA from escape mutations of the virus [4]. The secondary structures of virus genome RNAs of HCV and GBV-B around the target site are very similar to each other, and the designed siRNA was different from the corresponding sequence of HCV by only two nucleotides (Fig. 1).




Fig. 3. Effect of the GBV-B siRNA/cationic liposome complex on replication of GBV-B in marmosets.




Fig. 4. Side effects of siRNA/cationic liposome complex. (A) Induction of IFN- $\alpha$  was evaluated by measuring mouse serum 3 h after intravenous injection of 1–5 mg/kg GBV-B or control siRNA/cationic liposome complex ( $n = 3$ ). \* $<0.05$  (Student  $t$  test). (B) Induction of IFN- $\alpha$  and  $\gamma$  was evaluated by measuring marmoset serum 3 h after intravenous injection of 5 mg/kg GBV-B or control siRNA/cationic liposome complex, respectively ( $n = 3$ ). (C) Peripheral blood platelet was counted in the five marmosets examined in the same experiment shown in Fig. 3.

#### Effect of siRNA *in vitro* and *in mice*

First, we confirmed the efficient cleavage of GBV-B RNA by the siRNA in 293 T cells. The cells were harvested at 24 h of transfection with pGBV-B-Rluc, pRL-RSV and siRNA oligonucleotides, and internal luciferase activities were measured and ratio of RLuc versus FLuc value was calculated. More than 90% the RLuc activities were inhibited by expressing co-transfected siRNA (Fig. 2A). This result clearly indicated that GBV-B siRNA efficiently inhibited the expression of GBV-B RNA in culture cells.

Next, we investigated the *in vivo* effect of siRNA formulated in the cationic liposome on silencing the viral gene expression in the liver of mice. BALB/c mice were injected

intravenously from the tail vein with GBV-B CL-siRNA followed by hydrodynamically injection of pGBV-B-Rluc and pRL-RSV. We found that intravenously administered GBV-B CL-siRNA efficiently suppressed the expression of GBV-B genome in the liver of mice (Fig. 2B).

#### Effect of siRNA on GBV-B replication in marmosets

The 1.0, 2.5 and 5.0 mg/kg/day of siRNA to GBV-B, 5.0 mg/kg/day of control siRNA formulated by the cationic liposome, or just 10% maltose (sham) were administered by standard intravenous injections via the saphenous vein of the marmosets for three consecutive days. On the second day, GBV-B infectious serum

( $1.3 \times 10^9$  viral RNA copies/inoculum) was directly injected to the liver. Before and after the inoculation, GBV-B RNA in the serum was quantified by a real-time, 5' exonuclease PCR. In a sham-administered marmoset, the viral RNA was transiently increased in plasma after infection and the viral load reached to the peak level ( $3.6 \times 10^7$  copies/ml) (Fig. 3). It has been reported that GBV-B infection in marmosets as well as tamarins causes semi-acute viremia which generally ceases within 10–12 weeks post-infection [8,14,15]. This viral kinetics is consistent with the cases of HCV-infected human or chimpanzee, thus it appears to be *in vivo* characteristics of genus hepativirus where HCV and GBV-B belong to. Virological or immunological implication for the transient viremia is not fully addressed.

In contrast to sham-administered marmoset, we could find that the administration of CL-siRNA significantly delayed or suppressed the replication of GBV-B in a dose-dependent manner; the 5.0 mg/kg CL-siRNA completely suppressed the replication of GBV-B for more than 6 months after the infection (Fig. 3), even though the siRNA was administered only for the initial 3 days. Unexpectedly, the 5.0 mg/kg of control CL-siRNA was also able to delay the virus replication, while the peak level was comparable with that of the untreated monkey (Fig. 3).

#### Induction of interferons

We evaluated the induction of serum IFN- $\alpha$  by intravenous administration of the siRNA with cationic liposome in mice. IFN- $\alpha$  was induced by CL-siRNA but not by the cationic liposome nor siRNA oligonucleotide alone (data not shown). Induced IFN levels in the sera were dose-dependent and were significantly higher in mice with the control CL-siRNA than those with the GBV-B CL-siRNA (Fig. 4A).

An independent experiment using marmosets showed that single injection of 5.0 mg/kg control CL-siRNA substantially induced the serum interferon (IFN)- $\alpha$  and - $\gamma$ , whereas the same dose of CL-siRNA induced a minimal level of IFN- $\alpha$  and no detectable level of IFN- $\gamma$  (Fig. 4B).

In addition, a transient and mild decrease in peripheral blood platelets was more clearly observed in the marmoset treated with 5.0 mg/kg of control than 5.0 mg/kg of GBV-B CL-siRNA (Fig. 4C). There was no other remarkable abnormality related to siRNA administration in biochemical parameters indicating liver dysfunction which include alanine aminotransferase, aspartate aminotransferase, lactate dehydrogenase and albumin.

#### Discussion

Many viruses produce some dsRNA as a byproduct of their replication [16], and RNAi serves as an important defense against viruses in plants [17]. Therefore, mammalian viruses have been expected to be a good therapeutic target of RNAi, and indeed, several animal viruses have been successfully inhibited to replicate *in vitro* [18]. Locally

delivered siRNA have proven effective in abrogating infection from respiratory [19–22] and vaginal [23] viruses. Recently, systemically-delivered siRNA in mice has been successfully suppressed the expression of endogenous gene of the liver [24–26]. However, it remains to be ascertained if the RNAi-mediated gene therapy with systemically-delivered siRNA would be applicable to hepatitis virus in non-human primates. In this study, we examined if RNAi therapy could be effective toward infectious diseases by using a non-human primate surrogate model for hepatitis C. Administration into marmosets of CL-siRNA for GBV-B, which is most closely related to hepatitis C virus, repressed GBV-B replication in a dose-dependent manner. Our results suggest the feasibility of systemic administration of CL-siRNA as an antiviral strategy.

The 5.0 mg/kg GBV-B CL-siRNA dramatically inhibited the replication of GBV-B. However, control CL-siRNA also delayed the virus replication. Intravenous injection of siRNA formulated with liposomes was reported to stimulate mammalian immune system [26,27]. In relation to antiviral effect of IFNs, we therefore measured the serum IFN levels. Since the GBV-B siRNA/cationic liposome had less effect in IFN induction than the control but better antiviral effect than the control, it is possible that inhibition of the viral replication by the GBV-B siRNA/cationic liposome complex was at least in part caused by RNA interference. On the other side, it is also likely that IFN locally induced in the marmoset liver contributed the suppression of the viral replication. Because the induced level of mice serum IFN- $\alpha$  by GBV-B CL-siRNA was significant, although it was less than that by control CL-siRNA. Moreover, estimated IFNs level in marmoset serum was minimal but their actual levels might have been more, because the standard IFN in the ELISA was human or rhesus macaque IFN. Therefore, we considered that the antiviral effect of CL-siRNA was made by both RNA interference and induced IFNs.

In therapeutic application of siRNA to humans, general safety is a most important problem. The side effect of CL-siRNA to the liver is thought to consist of direct liver toxicity which is probably caused by its hydrophobic nature and its immuno-stimulatory effect [26–28]. Recently, Zimmermann et al. has reported that siRNA delivered systemically in a cationic liposome, stable nucleic acid lipid particles (SNALP), inhibited endogenous gene expression in the liver of the cynomolgus monkeys, which supports our notion concerning the therapeutic potential of systemically injected siRNA in primates. Although they made excellent chemical modifications to siRNA oligonucleotides to reduce IFN induction, their siRNA complex produced a considerable liver damage with a marked increase of transaminases at the dose (2.5 mg/kg) of maximal suppression effect. This indicated that the therapeutic window of their siRNA complex is overlapped with its toxic window. In contrast, our CL-siRNA induced much less liver damage, since even the 5.0 mg/kg of our CL-siRNA did not show a marked liver damage, but induced a sub-

stantial immune responses. A number of recent studies revealed that siRNA/cationic liposome complex has an immunological effects of siRNAs including the induction of proinflammatory cytokines and type I IFNs (IFN- $\alpha$  and IFN- $\beta$ ) through activation of RNA-sensing immunoreceptors including three members of the Toll-like receptor (TLR) family (TLR3, TLR7 and TLR8) [29]. Detection of siRNA molecules could trigger antiviral innate defense mechanisms including the induction of type I IFNs. In fact, double strand RNA molecule, poly I/C, was reported to eliminate the virus in GBV-B-infected tamarin hepatocytes by activating TLR3 [30,31]. These knowledges lead us to postulate that it is one of sophisticated strategy for siRNA to inhibit hepatitis virus to use this immuno-stimulatory side effect as an antiviral innate defense, only if the systemic side effects are tolerable.

#### Acknowledgments

We thank members of Corporation for Production and Research of Laboratory Primates for their technical support, N. Enomoto (Yamanashi University) for the invaluable suggestions and encouragements, and S. Arold (CNRS, France) for critical reviewing of the manuscript. RNAs and cationic liposome were supplied by Nippon Shinyaku Co., Ltd. This work was supported by Grants from the Ministry of Education, Science and Culture, Japan (#18390215, T.Y. and H.A.) and from the Ministry of Health, Labor and Welfare, Japan (#2212065, T.Y.; #17200101, H.A.).

#### References

- [1] G.J. Hannon, RNA interference, *Nature* 418 (2002) 244–251.
- [2] W.R. Kim, The burden of hepatitis C in the United States, *Hepatology* 36 (2002) S30–S34.
- [3] J.M. Mchutchison, Hepatitis C advances in antiviral therapy: what is accepted treatment now? *J. Gastroenterol. Hepatol.* 17 (2002) 431–441.
- [4] T. Yokota, N. Sakamoto, N. Enomoto, H. Tanabe, M. Maekawa, M. Miyagishi, K. Taira, M. Watanabe, H. Mizusawa, Inhibition of intracellular hepatitis C Virus replication by synthetic and vector-derived small interfering RNAs, *EMBO Rep.* 4 (2003) 602–608.
- [5] M.Y. Seo, S. Abrignani, M. Houghton, J.H. Han, Small interfering RNA-mediated inhibition of hepatitis C virus replication in the human hepatoma cell line Huh-7, *J. Virol.* 77 (2003) 810–812.
- [6] M. Korf, D. Jarczyk, C. Beger, M.P. Manns, M. Kruger, Inhibition of hepatitis C virus translation and subgenomic replication by siRNAs directed against highly conserved HCV sequence and cellular HCV cofactors, *J. Hepatol.* 43 (2005) 225–234.
- [7] A. Martin, F. Bodola, D.V. Sangar, K. Goette, V. Popov, R. Rijnsbrand, R.E. Lanford, S.M. Lemon, Chronic hepatitis associated with GB virus B persistence in a tamarin after intrahepatic inoculation of synthetic viral RNA, *Proc. Natl. Acad. Sci. USA* 100 (2003) 9962–9967.
- [8] K. Ishii, S. Iijima, N. Kimura, Y.-J. Lee, N. Ageyama, S. Yagi, K. Yamaguchi, N. Maki, K. Mori, S. Yoshizaki, S. Machida, T. Suzuki, N. Iwata, T. Sata, K. Terao, T. Miyamura, H. Akari, GBV-B as a pleiotropic virus: distribution of GBV-B in extrahepatic tissues in vivo, *Microb. Infect.* 9 (2007) 515–521.
- [9] K. Hirabayashi, J. Yano, T. Inoue, T. Yamaguchi, K. Tanigawara, G.E. Smyth, K. Ishiyama, T. Ohgi, K. Kimura, T. Irimura, Inhibition of cancer cell growth by polyinosinic-polycytidylic acid/cationic liposome complex: a new biological activity, *Cancer Res.* 59 (1999) 4325–4333.
- [10] J. Yano, K. Hirabayashi, S. Nakagawa, T. Yamaguchi, M. Nogawa, I. Kashimori, H. Naito, H. Kitagawa, K. Ishiyama, T. Ohgi, T. Irimura, Antitumor activity of small interfering RNA/cationic liposome complex in mouse models of cancer, *Clin. Cancer Res.* 10 (2004) 7721–7726.
- [11] M. Nogawa, T. Yuasa, S. Kimura, M. Tanaka, J. Kuroda, K. Sato, A. Yokota, M. Koizumi, T. Maekawa, Intravesical administration of small interfering RNA targeting PLK-1 successfully prevents the growth of bladder cancer, *J. Clin. Invest.* 115 (2005) 978–985.
- [12] F. Liu, Y.K. Song, D. Liu, Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA, *Gene Ther.* 6 (1999) 1258–1266.
- [13] A.A. Kolyhalov, K. Mihalik, S.M. Feinstone, C.M. Rice, Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3' nontranslated region are essential for virus replication in vivo, *J. Virol.* 74 (2000) 2046–2051.
- [14] J.R. Jacob, K.C. Lin, B.C. Tennant, K.G. Masnfield, GB virus B infection of the common marmoset (*Callithrix jacchus*) and associated liver pathology, *J. Gen. Virol.* 85 (2004) 2525–2533.
- [15] R.E. Lanford, D. Chavez, L. Notvall, K.M. Brasky, Comparison of tamarins and marmosets as hosts for GBV-B infections and the effect of immunosuppression on duration of viremia, *Virology* 311 (2003) 72–80.
- [16] B.L. Jacobs, J.O. Langland, When two strands are better than one: the mediators and modulators of the cellular responses to double-stranded RNA, *Virology* 219 (1996) 339–349.
- [17] M.T. Mcmanus, Small RNAs and immunity, *Immunity* 21 (2004) 747–756.
- [18] J.N. Leonard, D.V. Shaffer, Antiviral RNAi therapy: emerging approaches for hitting a moving target, *Gene Ther.* 13 (2006) 532–540.
- [19] V. Bitko, A. Musiyenko, O. Shulyayeva, S. Barik, Inhibition of respiratory viruses by nasally administered siRNA, *Nat. Med.* 11 (2005) 50–55.
- [20] W. Zhang, H. Yang, X. Kong, S. Mohapatra, H. San Juan-Vergara, G. Hellermann, S. Behera, R. Singam, R.F. Lockey, S.S. Mohapatra, Inhibition of respiratory syncytial virus infection with intranasal siRNA nanoparticles targeting the viral NS1 gene, *Nat. Med.* 11 (2005) 56–62.
- [21] B.J. Li, Q. Tang, D. Cheng, C. Qin, F.Y. Xie, Q. Wei, J. Xu, Y. Liu, B.J. Zheng, M.C. Woodle, N. Zhong, P.Y. Lu, Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque, *Nat. Med.* 11 (2005) 944–9451.
- [22] S.M. Tompkins, C.Y. Lo, T.M. Tumpey, S.L. Epstein, Protection against lethal influenza virus challenge by RNA interference in vivo, *Proc. Natl. Acad. Sci. USA* 101 (2004) 8682–8686.
- [23] D. Palliser, D. Chowdhury, Q.Y. Wang, S.J. Lee, R.T. Bronson, D.M. Knipe, J. Lieberman, An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection, *Nature* 439 (2006) 89–94.
- [24] J. Soutschek, A. Akinc, B. Bramlage, K. Charisse, R. Constien, M. Donoghue, S. Elbashir, A. Geick, P. Hadwiger, J. Harborth, M. John, V. Kesavan, G. Lavine, R.K. Pandey, T. Racie, K.G. Rajeev, I. Rohl, I. Toudjarska, G. Wang, S. Wuschko, D. Bumcrot, V. Kotliansky, S. Limmer, M. Manoharan, H.P. Vornlocher, M. Manoharan, H.P. Vornlocher, Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs, *Nature* 432 (2004) 173–178.
- [25] E. Song, P. Zhu, S.K. Lee, D. Chowdhury, D.M. Dykxhoorn, Y. Feng, D. Palliser, D.B. Weiner, P. Shankar, W.A. Marasco, J. Lieberman, Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors, *Nat. Biotechnol.* 23 (2005) 709–717.

- [26] D.V. Morrissey, J.A. Lockridge, L. Shaw, K. Blanchard, K. Jensen, W. Breen, K. Hartsough, L. Machemer, S. Radka, V. Jadhav, N. Vaish, S. Zinnen, C. Vargeese, K. Bowman, C.S. Shaffer, L.B. Jeffs, A. Judge, I. MacLachlan, B. Polisky, Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs, *Nat. Biotechnol.* 23 (2005) 1002–1007.
- [27] A.D. Judge, V. Sood, J.R. Shaw, D. Fang, K. McClintock, I. MacLachlan, Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA, *Nat. Biotechnol.* 23 (2005) 457–462.
- [28] T.S. Zimmermann, A.C. Lee, A. Akinc, B. Bramlage, D. Bumcrot, M.N. Fedoruk, J. Harborth, J.A. Heyes, L.B. Jeffs, M. John, A.D. Judge, K. Lam, K. McClintock, L.V. Nechev, L.R. Palmer, T. Racie, I. Rohl, S. Seiffert, S. Shanmugam, V. Sood, J. Soutschek, I. Toudjarska, A.J. Wheat, E. Yaworski, W. Zedalis, V. Kotliansky, M. Manoharan, H.P. Vornloche, I. MacLachlan, RNAi-mediated gene silencing in non-human primates, *Nature* 441 (2006) 111–114.
- [29] M. Schlee, V. Hornung, G. Hartmann, siRNA and isRNA: two edges of one sword, *Mol. Ther.* 14 (2006) 463–470.
- [30] R.E. Lanford, D. Chavez, B. Guerra, J.Y.N. Lau, Z. Hong, K.M. Brasky, B. Beames, Ribavirin induces error-prone replication of GB virus B in primary tamarin hepatocytes, *J. Virol.* 75 (2001) 8074–8081.
- [31] K. Li, Z. Chen, N. Kato, M. Gale Jr., S.M. Lemon, Distinct poly(I-C) and virus-activated signaling pathways leading to interferon-beta production in hepatocytes, *J. Biol. Chem.* 280 (2005) 16739–16747.